Journal of Neuro-Oncology

, Volume 79, Issue 2, pp 153–157 | Cite as

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial

  • A Taliansky-Aronov
  • F Bokstein
  • I Lavon
  • T SiegalEmail author
Clinical Patient Studies



Chemotherapy with alkylating agents is of proven efficacy in recurrent anaplastic oligodendroglioma (AO) with reported response rates ranging between 50% and 70%. The response of newly diagnosed AO to initial treatment with temozolomide (TMZ) has not yet been reported. This study evaluated the response and time to tumor progression of newly diagnosed AO initially treated with TMZ.

Patients and methods:

Twenty patients with a median age of 47 (range: 26–65) received a median of 14 (range: 3–24) cycles of TMZ as their first modality of therapy following diagnosis of AO. Treatment was given every 28 days for 5 days at a starting dose of 200 mg/m2/d and was continued for 24 cycles unless toxicity or tumor progression required withdrawal of TMZ. MRI evaluations were repeated every 8 weeks and scales of Karnofsky performance status (KPS) and of neurological function were used to assess clinical response.


Clinical improvement was observed in 60% of the patients with statistically significant gain measured by KPS and the neurologic function scales. The objective response rate was 75%, and median time to tumor progression was 24 months. Maximal objective response was reached within a median of 6 months (range: 3–12). Tumors with 1p loss had longer progression free survival compared to tumors without deletions (PFS at 24 months: 1p LOH  = 100%, 1p intact = 20%; P = 0.057). TMZ was well tolerated with only two events of grade 3/4 hematological toxicity.


Newly diagnosed AO demonstrates a high rate of response to initial therapy with TMZ, similar to the response reported for PCV combination therapy. Further studies are needed to determine the optimal duration of treatment and whether radiotherapy should immediately follow chemotherapy.


anaplastic oligodendroglioma clinical trial chemotherapy temozolomide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



  1. 1.
    Soffietti R, Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 5: 295–306, 2004PubMedCrossRefGoogle Scholar
  2. 2.
    van den Bent MJ, Kros JM, Heimans JJ, et al Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group Neurology 51: 1140–1145, 1998PubMedGoogle Scholar
  3. 3.
    Cairncross JG, Aggressive oligodendroglioma: a chemosensitive tumor. Recent Res Cancer Res 135: 127–133, 1994Google Scholar
  4. 4.
    van den Bent MJ, Taphoorn MJ, Brandes AA, et al: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525–2528, 2003PubMedCrossRefGoogle Scholar
  5. 5.
    van den Bent MJ, Chinot O, Boogerd W, et al: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14: 599–602, 2003PubMedCrossRefGoogle Scholar
  6. 6.
    Chinot OL, Honore S, Dufour H, et al Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449–2455, 2001PubMedGoogle Scholar
  7. 7.
    Yung WK, Prados MD, Yaya-Tur R, et al Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762–2771, 1999PubMedGoogle Scholar
  8. 8.
    Cairncross G, Seiferheld W, Shaw E, Jenkins R et al: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma: initial report of RTOG 94-02. Ninths Annual Meeting of the Society for Neuro-Oncology, November 18–21, 2004, Neuro-Oncology, 2004, p 371Google Scholar
  9. 9.
    van den Bent MJ, Diagnosis and management of oligodendroglioma. Semin Oncol 31: 645–652, 2004PubMedCrossRefGoogle Scholar
  10. 10.
    Cairncross G, Macdonald D, Ludwin S, et al Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013–2021, 1994PubMedGoogle Scholar
  11. 11.
    Lebrun C, Fontaine D, Ramaioli A, et al Long-term outcome of oligodendrogliomas. Neurology 62: 1783–1787, 2004PubMedGoogle Scholar
  12. 12.
    Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, et al High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma. J Neuro-Oncol 65: 127–134, 2003CrossRefGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • A Taliansky-Aronov
    • 1
  • F Bokstein
    • 2
  • I Lavon
    • 1
  • T Siegal
    • 1
    • 3
    Email author
  1. 1.Leslie and Michael Gaffin Center for Neuro-OncologyHadassah Hebrew University HospitalEin-Kerem, JerusalemIsrael
  2. 2.Neuro-Oncology ServiceSourasky Medical CenterTel AvivIsrael
  3. 3.Hadassah Hebrew University HospitalEin-Kerem, JerusalemIsrael

Personalised recommendations